Peptide Therapeutics intermediate
Milestone 013: Oligopeptide Research Reference
2014: First checkpoint inhibitor (ipilimumab) approved for melanoma. Opens era of cancer immunotherapy. This peptide or oligopeptide is studied for its biolo...
By Encyclopeptide Editorial | 1 min read
milestone-013 peptide research
Overview
2014: First checkpoint inhibitor (ipilimumab) approved for melanoma. Opens era of cancer immunotherapy.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Milestone 013” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Milestone 013: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept